Broadwood files preliminary proxy to block STAAR Surgical sale; company responds

STAAR Surgical's largest shareholder, Broadwood Partners, holding a 27.4% stake, has launched a formal proxy fight against Alcon AG's proposed $28-per-share acquisition, filing an SEC statement urging shareholders to reject the merger and associated executive change-of-control payouts. Broadwood contends the offer significantly undervalues STAAR, citing a prior $55-per-share Alcon bid and alleging the board stifled competing offers, while STAAR defends the $28 bid as a premium exit given market headwinds and lower growth prospects, particularly in China. This escalation introduces significant uncertainty into the acquisition, setting the stage for a contentious shareholder vote and potential further governance challenges.

Analysis

The proposed acquisition of STAAR Surgical (STAA) by Alcon (ALC) for $28 per share faces significant opposition, escalating into a formal proxy contest initiated by STAAR's largest shareholder, Broadwood Partners. Holding a 27.4% stake, Broadwood argues the offer materially undervalues the company, citing Alcon's own prior offer of $55 per share plus a $7 CVR in 2024 and a current valuation that represents a 15-20% discount to med-tech peers. The activist investor alleges the STAAR board conducted a flawed sale process that stifled competing bids and highlights a conflict of interest in the form of over $55 million in executive golden parachute payments. Conversely, STAAR's board defends the transaction as a compelling, premium value for shareholders, representing a 51% premium to the pre-announcement price. The board's rationale is predicated on substantial headwinds, including a sharp downturn and potential market saturation in China, its largest market, and competitive price pressure from alternatives like LASIK. This proxy fight introduces substantial event risk, with the deal's outcome contingent on a shareholder vote. Broadwood's position is strengthened by its belief that the deal is opportunistically timed ahead of a potential operational rebound and positive data from the upcoming 'EVOlve' clinical trial, while the likelihood of a competing offer diminishes rapidly after the September 19 expiration of the 'window-shop' period, when the termination fee quadruples.

Key Decisions for Investors

• Investors in STAAR Surgical must weigh the certainty of Alcon's $28 per share cash offer against the potential for a higher valuation if the deal is blocked, considering the significant risk that the stock could revert to its sub-$20 pre-announcement levels if the merger fails.
• Merger arbitrage specialists should note that Broadwood's 27.4% stake and formal proxy challenge substantially increase the risk of deal failure, and the arbitrage spread will be highly sensitive to any new developments or shifts in shareholder sentiment ahead of the vote.
• Fundamental investors should scrutinize the conflicting narratives on STAAR's standalone prospects, specifically the outlook for its China market, competitive positioning against LASIK, and the potential valuation impact of the upcoming EVOlve clinical trial data, which Broadwood cites as a key near-term catalyst.
• For Alcon shareholders, the deal represents a strategically sound acquisition at a price far below its 2024 offer, with the primary risk being the opportunity cost if the proxy battle leads to the deal's termination.